These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25060052)

  • 1. Serum fibroblast growth factor-23 is associated with incident kidney disease.
    Rebholz CM; Grams ME; Coresh J; Selvin E; Inker LA; Levey AS; Kimmel PL; Vasan RS; Eckfeldt JH; Feldman HI; Hsu CY; Lutsey PL;
    J Am Soc Nephrol; 2015 Jan; 26(1):192-200. PubMed ID: 25060052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women.
    Semba RD; Fink JC; Sun K; Cappola AR; Dalal M; Crasto C; Ferrucci L; Fried LP
    Clin J Am Soc Nephrol; 2012 Jan; 7(1):85-91. PubMed ID: 22076875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis.
    Anuwatmatee S; Allison MA; Shlipak MG; McClelland RL; Kramer H; Tang S; Hou L; Rye KA; Ong KL
    Nephrol Dial Transplant; 2019 Jun; 34(6):1009-1016. PubMed ID: 29771383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineral metabolites and CKD progression in African Americans.
    Scialla JJ; Astor BC; Isakova T; Xie H; Appel LJ; Wolf M
    J Am Soc Nephrol; 2013 Jan; 24(1):125-35. PubMed ID: 23243213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Hodakowski A; Lee J; Leonard M; Ricardo A; Chen J; Hamm L; Sondheimer J; Dobre M; David V; Yang W; Go A; Kusek JW; Feldman H; Wolf M; Isakova T;
    Clin J Am Soc Nephrol; 2017 Nov; 12(11):1795-1803. PubMed ID: 28784656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA; Wolf M; Jüppner H; Messinger S; Kumar J; Wesseling-Perry K; Schwartz GJ; Furth SL; Warady BA; Salusky IB
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):344-53. PubMed ID: 24311704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study.
    Ishigami J; Jaar BG; Rebholz CM; Grams ME; Michos ED; Wolf M; Kovesdy CP; Uchida S; Coresh J; Lutsey PL; Matsushita K
    J Clin Endocrinol Metab; 2017 Dec; 102(12):4648-4657. PubMed ID: 29029099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease.
    Kanbay M; Nicoleta M; Selcoki Y; Ikizek M; Aydin M; Eryonucu B; Duranay M; Akcay A; Armutcu F; Covic A
    Clin J Am Soc Nephrol; 2010 Oct; 5(10):1780-6. PubMed ID: 20576822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study.
    Lutsey PL; Alonso A; Selvin E; Pankow JS; Michos ED; Agarwal SK; Loehr LR; Eckfeldt JH; Coresh J
    J Am Heart Assoc; 2014 Jun; 3(3):e000936. PubMed ID: 24922628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.
    Nakano C; Hamano T; Fujii N; Obi Y; Matsui I; Tomida K; Mikami S; Inoue K; Shimomura A; Nagasawa Y; Okada N; Tsubakihara Y; Rakugi H; Isaka Y
    Bone; 2012 Jun; 50(6):1266-74. PubMed ID: 22425694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
    Fliser D; Kollerits B; Neyer U; Ankerst DP; Lhotta K; Lingenhel A; Ritz E; Kronenberg F; ; Kuen E; König P; Kraatz G; Mann JF; Müller GA; Köhler H; Riegler P
    J Am Soc Nephrol; 2007 Sep; 18(9):2600-8. PubMed ID: 17656479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study.
    Fyfe-Johnson AL; Alonso A; Selvin E; Bower JK; Pankow JS; Agarwal SK; Lutsey PL
    J Hypertens; 2016 Jul; 34(7):1266-72. PubMed ID: 27100793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum 25-hydroxyvitamin D level and kidney function decline in a Swiss general adult population.
    Guessous I; McClellan W; Kleinbaum D; Vaccarino V; Hugues H; Boulat O; Marques-Vidal P; Paccaud F; Theler JM; Gaspoz JM; Burnier M; Waeber G; Vollenweider P; Bochud M
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1162-9. PubMed ID: 25901090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of Vitamin D Status and Risk of ESRD.
    Rebholz CM; Grams ME; Lutsey PL; Hoofnagle AN; Misialek JR; Inker LA; Levey AS; Selvin E; Hsu CY; Kimmel PL; Vasan RS; Eckfeldt JH; Coresh J;
    Am J Kidney Dis; 2016 Feb; 67(2):235-42. PubMed ID: 26475393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.
    Ärnlöv J; Carlsson AC; Sundström J; Ingelsson E; Larsson A; Lind L; Larsson TE
    Clin J Am Soc Nephrol; 2013 May; 8(5):781-6. PubMed ID: 23335040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.
    Young A; Hodsman AB; Boudville N; Geddes C; Gill J; Goltzman D; Jassal SV; Klarenbach S; Knoll G; Muirhead N; Prasad GV; Treleaven D; Garg AX;
    Am J Kidney Dis; 2012 Jun; 59(6):761-9. PubMed ID: 22093959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
    Nakano C; Hamano T; Fujii N; Matsui I; Tomida K; Mikami S; Inoue K; Obi Y; Okada N; Tsubakihara Y; Isaka Y; Rakugi H
    Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
    Isakova T; Xie H; Yang W; Xie D; Anderson AH; Scialla J; Wahl P; Gutiérrez OM; Steigerwalt S; He J; Schwartz S; Lo J; Ojo A; Sondheimer J; Hsu CY; Lash J; Leonard M; Kusek JW; Feldman HI; Wolf M;
    JAMA; 2011 Jun; 305(23):2432-9. PubMed ID: 21673295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Socioeconomic status and risk of kidney dysfunction: the Atherosclerosis Risk in Communities study.
    Vart P; Grams ME; Ballew SH; Woodward M; Coresh J; Matsushita K
    Nephrol Dial Transplant; 2019 Aug; 34(8):1361-1368. PubMed ID: 29897587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.